Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia
Michele Milella, … , Elihu Estey, Michael Andreeff
Michele Milella, … , Elihu Estey, Michael Andreeff
Published September 15, 2001
Citation Information: J Clin Invest. 2001;108(6):851-859. https://doi.org/10.1172/JCI12807.
View: Text | PDF
Article Article has an altmetric score of 3

Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia

  • Text
  • PDF
Abstract

The mitogen-activated protein kinase (MAPK) pathway regulates growth and survival of many cell types, and its constitutive activation has been implicated in the pathogenesis of a variety of malignancies. In this study we demonstrate that small-molecule MEK inhibitors (PD98059 and PD184352) profoundly impair cell growth and survival of acute myeloid leukemia (AML) cell lines and primary samples with constitutive MAPK activation. These agents abrogate the clonogenicity of leukemic cells but have minimal effects on normal hematopoietic progenitors. MEK blockade also results in sensitization to spontaneous and drug-induced apoptosis. At a molecular level, these effects correlate with modulation of the expression of cyclin-dependent kinase inhibitors (p27Kip1 and p21Waf1/CIP1) and antiapoptotic proteins of the inhibitor of apoptosis proteins (IAP) and Bcl-2 families. Interruption of constitutive MEK/MAPK signaling therefore represents a promising therapeutic strategy in AML.

Authors

Michele Milella, Steven M. Kornblau, Zeev Estrov, Bing Z. Carter, Hélène Lapillonne, David Harris, Marina Konopleva, Shourong Zhao, Elihu Estey, Michael Andreeff

×

Total citations by year

Year: 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2003 2002 Total
Citations: 2 2 6 6 4 7 8 5 8 4 7 7 4 5 14 9 5 2 3 1 3 1 113
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article in year 2016 (8)

Title and authors Publication Year
The MEK Inhibitor Trametinib Separates Murine Graft-versus-Host Disease from Graft-versus-Tumor Effects
Hidekazu Itamura, Takero Shindo, Isao Tawara, Yasushi Kubota, Ryusho Kariya, Seiji Okada, Krishna V. Komanduri, Shinya Kimura
JCI Insight 2016
CD98-Mediated Adhesive Signaling Enables the Establishment and Propagation of Acute Myelogenous Leukemia
J Bajaj, T Konuma, NK Lytle, HY Kwon, JN Ablack, JM Cantor, D Rizzieri, C Chuah, VG Oehler, EH Broome, ED Ball, EH van der Horst, MH Ginsberg, T Reya
Cancer Cell 2016
Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS -mutant relapsed or refractory myeloid malignancies: Trametinib in RAS -Mutant Malignancies
G Borthakur, L Popplewell, M Boyiadzis, J Foran, U Platzbecker, N Vey, RB Walter, R Olin, A Raza, A Giagounidis, A Al-Kali, E Jabbour, T Kadia, G Garcia-Manero, JW Bauman, Y Wu, Y Liu, D Schramek, DS Cox, P Wissel, H Kantarjian
Cancer 2016
Tetraspanin CD82 Regulates the Spatiotemporal Dynamics of PKCα in Acute Myeloid Leukemia
CM Termini, KA Lidke, JM Gillette
Scientific Reports 2016
The HER2 inhibitor TAK165 Sensitizes Human Acute Myeloid Leukemia Cells to Retinoic Acid-Induced Myeloid Differentiation by activating MEK/ERK mediated RARα/STAT1 axis
X Shao, Y Liu, Y Li, M Xian, Q Zhou, B Yang, M Ying, Q He
Scientific Reports 2016
Tobacco Smoke and Ras Mutations Among Latino and Non-Latino Children with Acute Lymphoblastic Leukemia
M Kaur, AJ de Smith, S Selvin, L Zhang, M Cunningham, MW Kang, HM Hansen, RM Cooper, R McKean-Cowdin, JL Wiemels, C Metayer
Archives of Medical Research 2016
Analyzing tumor heterogeneity and driver genes in single myeloid leukemia cells with SBCapSeq
KM Mann, JY Newberg, MA Black, DJ Jones, F Amaya-Manzanares, L Guzman-Rojas, T Kodama, JM Ward, AG Rust, L van der Weyden, CC Yew, JL Waters, ML Leung, K Rogers, SM Rogers, LA McNoe, L Selvanesan, N Navin, NA Jenkins, NG Copeland, MB Mann
Nature Biotechnology 2016
Down-Regulation of Ribosomal S6 kinase RPS6KA6 in Acute Myeloid Leukemia Patients.
Rafiee M, Keramati MR, Ayatollahi H, Sadeghian MH, Barzegar M, Asgharzadeh A, Alinejad M
2016

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 1 patents
78 readers on Mendeley
See more details